Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositis

Milo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration ’s (FDA) Office of Orphan Products Development for treatment of inclusion body myositis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news